Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tuaminoheptane is a sympathomimetic agent and vasoconstrictor primarily used as a nasal decongestant for the symptomatic relief of nasal congestion, sinusitis, and rhinitis. It acts as a norepinephrine reuptake inhibitor and releasing agent, increasing norepinephrine levels in the synaptic cleft, which leads to vasoconstriction in the nasal passages and subsequent decongestion. Its stimulant effects are also attributed to this mechanism. Tuaminoheptane has been used both alone and in combination with other agents such as acetylcysteine. While it was formerly more widely available (including oral preparations), its use is now limited due to concerns about efficacy and side effects such as skin irritation, tachycardia, hypertension, and potential for abuse. It remains on the World Anti-Doping Agency's list of prohibited substances due to its stimulant properties[1][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tuaminoheptane.